Key result
Zotarolimus inhibits SMC proliferation and reduces cytokines while sparing EC viability and migration unlike paclitaxel.
Why the study?
Does transient exposure to zotarolimus compared to paclitaxel differentially affect vascular cell proliferation, migration, viability, and inflammation in vitro?
Does transient exposure to zotarolimus compared to paclitaxel differentially affect vascular cell proliferation, migration, viability, and inflammation in vitro?
In vitro, transient zotarolimus exposure inhibits smooth muscle cell proliferation and reduces inflammation while preserving endothelial cell viability and migration, unlike paclitaxel which reduces overall cell viability and endothelial migration.
Answers are grounded in this paper and cite their sources.
Zotarolimus may favor reendothelialization in transient-exposure devices; in vitro findings leave open clinical translation for drug-coated balloons.
Both paclitaxel and zotarolimus are currently employed in vascular interventional therapies, such as drug-eluting stents, and are under investigation for use in other novel drug-device combination products. Paclitaxel is a microtubule-stabilizing compound with potent antiproliferative properties and antimigration effects, whereas zotarolimus is a potent mammalian target of rapamycin inhibitor with antiproliferative and antiinflammatory properties. This study was intended to compare paclitaxel and zotarolimus for intravascular applications in which drug exposure time may be reduced, such as in drug-coated balloons. These applications are generally aimed at reducing neointimal hyperplasia by limiting smooth muscle cell (SMC) proliferation and inflammatory cell recruitment, while minimally interfering with vessel reendothelialization after balloon denudation. In the cellular models described in this study, transient exposure of zotarolimus resulted in the sustained inhibition of SMC proliferation and reduced endothelial cell (EC) proinflammatory cytokine expression, while not affecting EC migration and viability. Transient exposure of paclitaxel inhibited SMC proliferation, EC migration, and overall cell viability, with no effect on expression of the proinflammatory biomarkers studied.
No takes yet. Share an insight, caveat, or question.
Steinfeld et al. (2012) studied In vitro vascular cell models. Zotarolimus vs. Paclitaxel was evaluated on Smooth muscle cell proliferation, endothelial cell migration, viability, and proinflammatory biomarker expression. Transient exposure to zotarolimus inhibited SMC proliferation and reduced EC proinflammatory cytokines without affecting EC migration and viability, whereas paclitaxel inhibited migration and viability.
Synapse has enriched 10 related papers. Consider them for comparative context: